Biocon, Asia’s premier biopharmaceuticals company, has inaugurated a world class facility for manufacturing new generation, patient-friendly devices for its insulins portfolio. The 100,000 square feet, state-of-the-art new devices facility set up in Bangalore will enable the company to leverage the country’s manufacturing expertise to develop world-class delivery devices for people with diabetes in India and other parts of the world.
The pharma major has also launched Basalog One, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility. Basalog One, a long acting basal insulin glargine presented as an innovative, pre-filled pen, is the first product to roll out of this facility.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1658.30 |
| Dr. Reddys Lab | 1218.90 |
| Cipla | 1230.95 |
| Zydus Lifesciences | 931.80 |
| Lupin | 2313.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: